ASCO GU 2026: Updates in renal cancer
Published on 17 March 2026
Dr María Natalia Gandur Quiroga speaks to ecancer about the updates in renal cancer at ASCO GU 2026.
She says that renal carcinoma (RCC) has entered a new era, shifting from traditional VEGF-driven approaches to a more biologically integrated treatment strategy.
In this expert review, Dr Gandur explores how immunotherapy, HIF-2α inhibition, and emerging biomarkers are reshaping treatment across disease stages, from adjuvant therapy to post-immunotherapy sequencing.
| Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study | |
| LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC) | |
| Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model |